Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 13/20 | 0.49 |
| ▸ | PPARG | P37231 | 11/20 | 0.49 |
| ▸ | TARBP2 | Q15633 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3609694 | 0.94 | PPARA (0.55) | PPARAPPARGTARBP2SMN1; SMN2L3MBTL1 | |
| SCHEMBL3623449 | 0.91 | PPARA (0.49) | PPARAPPARGTARBP2SMN1; SMN2CYP2C9 | |
| SCHEMBL3619637 | 0.91 | PPARA (0.49) | PPARAPPARGTARBP2SMN1; SMN2CYP2C9 | |
| SCHEMBL3613267 | 0.90 | PPARA (0.48) | PPARAPPARGTARBP2SMN1; SMN2CYP2C9 | |
| SCHEMBL3612881 | 0.89 | PPARA (0.54) | PPARAPPARGTARBP2CYP2C9KCNH2 | |
| SCHEMBL3620218 | 0.89 | PPARG (0.47) | PPARAPPARGTARBP2CYP2C9KCNH2 | |
| SCHEMBL3603476 | 0.85 | PPARG (0.47) | PPARAPPARGTARBP2SMN1; SMN2CYP2C9 | |
| SCHEMBL3620095 | 0.85 | PPARG (0.47) | PPARAPPARGTARBP2SMN1; SMN2POLB | |
| SCHEMBL3623438 | 0.83 | PPARG (0.43) | PPARAPPARGTARBP2SMN1; SMN2CYP2C9 | |
| SCHEMBL3612297 | 0.83 | PPARG (0.43) | PPARAPPARGTARBP2SMN1; SMN2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022541-A1 | Chemical inhibitors of bacterial heptose synthesis, methods for their preparation and biological applications of said inhibitors | MUTABILIS SA (FR) | 2010-01-28 | — | — | US | disclosed |
| US-20100022541-A1 | Chemical inhibitors of bacterial heptose synthesis, methods for their preparation and biological applications of said inhibitors | MUTABILIS SA (FR) | 2010-01-28 | — | — | US | disclosed |
| US-20100022541-A1 | Chemical inhibitors of bacterial heptose synthesis, methods for their preparation and biological applications of said inhibitors | MUTABILIS SA (FR) | 2010-01-28 | — | — | US | disclosed |
| EP-2104671-A2 | SUBSTITUTED HETEROCYCLYLCARBONYLAMINO-ACETIC-ACID-DERIVATIVES AS INHIBITORS OF BACTERIAL HEPTOSE SYNTHESIS, METHODS FOR THEIR PREPARATION AND BIOLOGICAL APPLICATIONS OF SAID INHIBITORS | Mutabilis SA (FR) | 2009-09-30 | — | — | EP | disclosed |
| WO-2008038136-A2 | SUBSTITUTED HETEROCYCLYLCARBONYLAMINO-ACETIC-ACID-DERIVATIVES AS INHIBITORS OF BACTERIAL HEPTOSE SYNTHESIS, METHODS FOR THEIR PREPARATION AND BIOLOGICAL APPLICATIONS OF SAID INHIBITORS | MUTABILIS SA (FR) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008038136-A2 | SUBSTITUTED HETEROCYCLYLCARBONYLAMINO-ACETIC-ACID-DERIVATIVES AS INHIBITORS OF BACTERIAL HEPTOSE SYNTHESIS, METHODS FOR THEIR PREPARATION AND BIOLOGICAL APPLICATIONS OF SAID INHIBITORS | MUTABILIS SA (FR) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022541-A1 | Chemical inhibitors of bacterial heptose synthesis, methods for their preparation and biological applications of said inhibitors | CBR1, OXER1, CBR3 | PPARA 2162/4885PPARG 1817/4885TARBP2 3459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.